ISO/IEC 42001 is the world’s first international management system standard focused on AI governance. For pharma, it can function as a structured way to demonstrate “responsible AI” controls to partners, auditors, and regulators, especially for supplier oversight and internal AI governance.
Why it matters: Provides a management-system framework to govern AI risks (transparency, accountability, continual improvement) — useful when deploying GenAI/ML in regulated workflows.
What to watch: Increasing use of ISO/IEC 42001 in vendor qualification, AI governance programs, and as a “compliance bridge” alongside EU AI Act / GxP expectations.
FDA issued a Warning Letter to Purolea Cosmetics Lab that includes a dedicated section on AI use in cGMP. FDA states the firm used AI agents to create drug product specifications, procedures, and master production/control records. FDA’s key message is that AI-generated documents must be reviewed by humans (Quality Unit responsibility) and that “overreliance” on AI is unacceptable (including the firm stating it didn’t perform process validation because the AI “never told them” it was required).
Why it matters for pharma: This is a clear enforcement signal: AI can be used as a drafting aid, but it cannot replace QMS responsibilities (review/approval, validation, compliance checks, documented oversight).
This report (written with input from 100+ independent experts across many countries and organisations) synthesises what frontier/general-purpose AI systems can do, what risks they pose, and how those risks can be managed. For pharma companies deploying GenAI/LLMs (quality, PV, medical writing, knowledge systems), it is a practical reference for “known failure modes” (evaluation gaps, reliability issues, misuse risks) and governance expectations.
International AI Safety Report 2026: what matters for pharma (quick take)
The International AI Safety Report 2026 (Feb 2026) is not a pharma-specific guidance, but it contains several points that are highly relevant for pharmaceutical companies using GenAI/LLMs or “AI agents” in R&D, labs, medical information, PV, quality systems, and regulated documentation.
Notably, the report highlights the following pharma-relevant themes:
AI as a scientific accelerator (with dual-use implications). Advanced AI can support tasks such as molecule/protein design and other scientific work that can accelerate drug discovery, while also raising dual-use concerns (bio/chem misuse risk).
Growing capability of AI agents in laboratory contexts. The report discusses increasingly capable agents (“AI co-scientists”) that can assist with experimental protocols, troubleshooting, and interacting with biological tools—useful for legitimate research but also relevant for risk governance.
Use of “benign proxy tasks” in bio/chem risk evaluation. Because direct weapons testing is constrained, the report notes that safer proxy tasks—explicitly including activities like pharmaceutical synthesis—are used to estimate how much AI can increase capability.
The “evaluation gap” as a central governance warning. Models can look strong in benchmarks but behave differently in real-world settings. For pharma, this directly supports the need for realistic testing, monitoring, and lifecycle control before relying on AI outputs in high-stakes processes.
Reliability risks in high-stakes domains like medicine. The report highlights known failure modes (e.g., hallucinations/out-of-distribution failures) and notes that these issues matter in medical contexts, reinforcing the need for boundaries and human oversight.
Safety practices that map well to pharma governance. The report emphasizes practices such as red-teaming and monitoring/control approaches, which align well with regulated “fit-for-intended-use” thinking and ongoing oversight.
Practical takeaway: this report strengthens the argument that GenAI and agentic systems should be treated as probabilistic tools with real failure modes—requiring realistic evaluation, red-teaming, monitoring, and clear boundaries, especially when outputs influence regulated decisions.
